Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China

Overview of attention for article published in Health Economics Review, January 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 3 Mendeley

So far, Altmetric has seen 1 X post from an account with 17 followers.

Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China https://t.co/smPEyfWSvO

24 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.